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Abstract: Newly arrived migrants to the EU/EEA (arrival within the past five years), as well
as other migrant groups in the region, might be under-immunised and lack documentation of
previous vaccinations, putting them at increased risk of vaccine-preventable diseases circulating
in Europe. We therefore performed a systematic review conforming to PRISMA guidelines
(PROSPERO CRD42016045798) to explore: (i) interventions that improve vaccine uptake among
migrants; and (ii) cost-effectiveness of vaccination strategies among this population. We searched
MEDLINE, Embase, CINAHL, and Cochrane Database of Systematic Reviews (CDSR) between 1
January 2006 to 18 June 2018. We included three primary intervention studies performed in the
EU/EEA or high-income countries and one cost effectiveness study relevant to vaccinations in
migrants. Intervention studies showed small but promising impact only on vaccine uptake with
social mobilization/community outreach, planned vaccination programs and education campaigns.
Targeting migrants for catch-up vaccination is cost effective for presumptive vaccination for
diphtheria, tetanus, and polio, and there was no evidence of benefit of carrying out pre-vaccination
serological testing. The cost-effectiveness is sensitive to the seroprevalence and adherence to
vaccinations of the migrant. We conclude that scarce but direct EU/EEA data suggest social
mobilization, vaccine programs, and education campaigns are promising strategies for migrants, but
more research is needed. Research should also study cost effectiveness of strategies. Vaccination of
migrants should continue to be a public heath priority in EU/EEA.
Int. J. Environ. Res. Public Health 2018, 15, 2065; doi:10.3390/ijerph15102065 www.mdpi.com/journal/ijerph
Int. J. Environ. Res. Public Health 2018, 15, 2065 2 of 13
Keywords: VPD; immunisation strategies; health systems; refugees; migrants; cost effectiveness
1. Introduction
Globally, there are over 258 million people who migrate across international borders, including
labour migrants, students, refugees, asylum seekers, undocumented migrants, and other migrant
groups [1]. Another 763 million people migrate internally [2]. In the European Union/European
Economic Area (EU/EEA) in particular, there has been an unprecedented number of refugees and
other migrants between 2014 and 2016 linked to the Syrian war [3], other armed conflicts, climate
change and economic crises. In addition, there are around 40 million EU migrants who have moved
internally from one European country to another [4].
Control of vaccine preventable diseases (VPDs) is a priority in the EU/EEA [5]. Very little
information is available on the occurrence of vaccine preventable diseases specifically among newly
arrived migrant populations in the EU/EEA. Although national surveillance systems for VPDs are in
place and regular reporting occurs, surveillance is incomplete for migrant health data such as country
of birth and time since arrival. There have been EU/EEA measles and polio outbreaks that have
been related to under-immunised migrant populations [6–10], but outbreaks have also occurred in
non-migrant populations [11–14]. The 2017/2018 pan-European measles epidemic involved internal
EU/EEA migrants moving between countries, so it is important also to consider this group alongside
migrants arriving from outside of the EU/EEA [15].
Seroprevalence studies have demonstrated sub-optimal immunity to VPD among adult and child
migrants [16–24]. Further, the WHO’s global data on immunisation coverage report sub-optimal
immunisation among the general population worldwide, with global coverage ranging 47–85%
depending on the vaccine and even greater variation between geographical region [25]. This includes
the EU/EEA, where some countries have not achieved target vaccine coverage with regards to,
for example, first dose measles. Among all types of migrants from the top ten countries of birth
arriving to the EU/EEA, the range of age-appropriate (i.e., two-dose) measles vaccination coverage
ranges 31–99% [26]. Sub-optimal immunity has implications for maintaining herd immunity to
minimize outbreaks where seropositivity thresholds within 80–94% are required [25,27]. Collective
immunity below these thresholds, whether it is the native-born population, newly-arrived migrants,
or a combination, carries the inherent risk of disease transmission and outbreak.
A recent cross-sectional survey study of EU/EEA countries “immigrant” measles vaccination
policy demonstrated a significant diversity in strategies with 9 of 31 states having no policy.
The remaining 22 states′ policies differed widely in utilizing age, immunisation status, method for
assessing immunisation status and immigrant type [28]. Furthermore, vaccination policies tailored to
migrants and refugees are heterogenous across WHO European region member states [29]. Vaccinations
are effective, but there are no specific data on effective implementation strategies for immunization in
migrants to EU/EEA. We therefore performed a systematic review to address: (i) what interventions
increase uptake of vaccinations in migrants; and (ii) cost-effectiveness of vaccination strategies
among migrants.
2. Methods
Using the Grading of Recommendations Assessment, Development and Evaluation (GRADE)
approach, the Campbell and Cochrane Collaboration Equity Methods Group and review team,
including clinicians, public health experts and researchers from across the EU/EEA, conducted
evidence syntheses. A detailed description of the methods can be found in the registered systematic
review protocol [30].
The review group followed the PRISMA Reporting guideline [31] for the reporting of this
systematic review (PROSPERO CRD42016045798). In summary, the review team developed key
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research questions and a logic model showing an evidence chain to identify key concepts, to
consider the potential role of indirect evidence related to populations and interventions and to
support the formulation of search strategies (Supplementary Materials). We aimed to answer the
following questions:
What interventions increase the uptake of vaccinations in migrants?
What are cost-effective strategies for vaccinating migrants?
We developed our inclusion and exclusion criteria based on the PICO model (population,
intervention, comparator and outcome). “Migrants,” a focus for the eligible evidence, included
asylum seekers, refugees, undocumented migrants, and other foreign-born residents, with a focus on
newly arrived migrants as defined in the protocol as within five years of arrival to the destination
country [30]. Internal EU migrants were also included to reflect the large movement of migrants
within the EU who were new to the EU/EEA. Only papers addressing migrants to the EU/EEA or
other high-income countries were included in the final synthesis. The intervention included any
strategy to increase vaccination. The comparators were migrants not exposed to the intervention. We
considered the following outcomes: uptake of vaccination and completion of vaccination; disease
incidence rates for measles, congenital rubella, diphtheria pertussis, tetanus, Hib, and polio among
migrant populations; and cost effectiveness.
Using relevant search terms and strategies, we searched published literature from 1 January
2006 to 18 June 2018 in MEDLINE, Embase, CINAHL, and Cochrane Database of Systematic Reviews
(CDSR) for interventions to improve vaccine uptake (File Supplementary A). Searches were designed
and conducted by librarian experienced in systematic reviews using a method designed to optimize
term selection [32]. The MEDLINE search was validated by testing its ability to retrieve the eligible
studies found from the initial search. All were indexed in MEDLINE and the search retrieval was
95%, thus the search was not modified before the final update was run [33]. For economic studies,
we searched MEDLINE, Database of Abstracts of Reviews of Effects (DARE), (CDSR) and EMBASE
from 1 January 2006 to 26 May 2016, and in addition, NHS EED, CEA Registry (Tufts University) and
Google Scholar from 1995 to 2016 (File Supplementary B). No language restrictions were applied to
both searches.
For the intervention studies, at least two reviewers (JD, CH, JB, and NN) independently reviewed
the titles and abstracts of the papers identified from the search, identifying them as “included” or
“not included” based on previously described inclusion/exclusion criteria. Any conflicts were then
resolved through discussion by the two review leads (CH and JD). At the second level screening, two
independent reviewers performed a full text review per paper (JD, CH, JB, and NN). Conflicts were
again resolved via discussion by review leads (CH and JD). The quality of nonrandomized studies was
assessed using the Newcastle–Ottawa Scale (NOS) [34]. No studies were excluded based on the NOS.
For the cost effectiveness studies, two reviewers independently reviewed all full text articles
(LS and AT) and extracted relevant data from the primary studies that met our inclusion criteria
including the economic study design (e.g., micro-costing study, within-trial cost-utility analysis,
and decision-analytic model); the intervention and comparator; the difference in resource use;
cost-effectiveness results (e.g., incremental net benefit or incremental cost-effectiveness ratio);
the certainty of evidence around resource requirements; and whether the cost-effectiveness results
favoured the intervention or comparator. Finally, we assessed the certainty of economic evidence in
each study using the relevant items from the 1997 Drummond checklist [35].
3. Results
3.1. What Interventions Increase Uptake of Vaccinations in Migrants?
The search for interventions that increase uptake of vaccinations identified 2970 studies. Three studies
were included in the final analysis [36–38] (PRISMA Flow Diagram Figure 1). After assessment with the
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Newcastle–Ottawa Scale (NOS; Table 1), two were determined to be of medium quality [36,38] (NOS 4–6),
and one was a low quality study [37] (NOS < 4).Int. J. Environ. Res. Public Health 2018, 15, x  4 of 13 
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Table 1. Characteristics of included studies in high income countries—strategies to increase vaccination uptake.
Study Quality 1 Type of study Setting (Country) Population Intervention Results/Outcomes
Brockmann,
2016 [38] 4/10 Cohort study
Housing units
(Germany)
Children,
adolescent, adult
asylum seekers
Vaccination “concept” facilitated by local
public health office:
(1) Written letters and posters informing
about VPDs
(2) In person communication about VPDs
(3) Invitations to onsite
vaccination campaigns
(4) Informational vaccine material in
various languages and via interpreters
58% of refugees exposed to concept
were vaccinated compared to 6% of
refugees vaccinated in facilities without
the intervention
Milne, 2006
[36] 4/10
Cross-sectional:
assessing uptake of
MMR, HepB
School (Australia)
Refugee
adolescents,
young adults
(1) Self-report survey on immunisation
status and primary health care use,
with provision of 1 dose MMR.
(2) Letter given to student with due date f
and written referral to GP; list of GPs
and spoken languages available
74% students received MMR vaccine
30% historical vaccination rate
Spadea, 2014
[37] 2/10
Cross-sectional:
assessing uptake of
MMR and hexavalent
(DPT-Hib-IPV-HepB)
Nomadic camp (Italy)
Roma children
and women of
childbearing age
Vaccination day held on monthly basis
56.4% coverage of hexavalent vaccine
(range 44–91%) at three camps
58.4% coverage of MMR vaccine (range
53–83%) at three camps
30% increase in vaccinations compared
with previous year
1 The quality of evidence was assessed using the Newcastle–Ottawa Scale (NOS); rated out of 10 for cross-sectional studies, and out of 9 for case-control or cohort studies.
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Of the two studies that were performed in Europe, one was cohort study of asylum seekers
living in housing units in Germany employed a vaccination strategy using multiple different
interventions [38]. The local public health office informed asylees about relevant VPDs in written
letters and posters, as well as in person, and invited them to on-site vaccination campaigns. General
practitioners carried out the actual vaccination. Information material regarding vaccination was
provided in various languages and via interpreters. Vaccination “certificates” were also provided.
In areas utilizing this vaccination strategy, 58% of refugees were vaccinated compared to 6% of
refugees vaccinated in facilities without the intervention. Of the total 642 asylees who were vaccinated,
86% received their immunization within the vaccine intervention program. There was a particular
focus on male adult asylees who had an eight-fold increase in vaccinations through the strategy.
Of note, the program purchased vaccines directly from the manufacturer, saving 50% of the cost
compared to buying from a pharmacy. A second European study involved Roma children and women
of childbearing age in a nomadic camp in Rome. As part of a tuberculosis outbreak assessment, a
monthly vaccination day led to a 56% coverage of hexavalent vaccines and a 58% coverage of MMR
vaccines which was a 30% increase in vaccinated subjects compared with the previous year [37].
The third study that was performed in a high income country was a study of refugee adolescents
and young adults in an Intensive English Centre high school in Australia employed a survey of
immunisation status [36]. The intervention involved the school-based provision of MMR and the
first and second dose of a three-dose hepatitis B schedule following an immunisation survey. Of the
165 students who completed the survey (85%), 74% received measles, mumps and rubella (MMR)
vaccine in the school as compared with historic levels of 30%. Of the students who received a second
dose of hepatitis B vaccine in the school-based program, less than 24% finished the series with a
primary care clinician.
3.2. What are Cost-Effective Approaches to Vaccinating Newly Arrived Migrants?
We identified 810 articles for screening. One article conducted among migrants was included in
the final analysis [39] (PRISMA flow diagram Figure 2). This cost-effectiveness study was assessed to
be of moderate quality using the Drummond checklist. One-way and two-way sensitivity analyses
were undertaken, and the cost-effectiveness results were tested for changes across plausible ranges
of estimates for costs of serotesting, compliance rates and seroprevalence. Probabilistic sensitivity
analyses were not reported.
Results of the economic study are presented in Table 2. This study among migrants compared
pre-vaccination serotesting with presumptive vaccination for polio, diphtheria, and tetanus in
internationally adopted and immigrant infants to the US [39]. It showed that compared with presumptive
vaccination, pre-vaccination serotesting for polio increased the cost per patient from $57 USD to $62 USD
(in 2004 dollars) and decreased the percentage of patients protected against polio from 95.3% to 94.0%.
Presumptive vaccination was more effective and less expensive than pre-vaccination serotesting when the
seroprevalence was <69%. Presumptive vaccination was the preferred method unless the vaccination
compliance was extremely high (>96% completion rate). In the same study, the results for diphtheria,
tetanus, and acellular pertussis (DTaP) were less definitive. Pre-vaccination serotesting for diphtheria and
tetanus increased the cost per patient from $62 USD to $119 USD and increased the percentage of patients
protected against both diphtheria and tetanus from 91.5% to 92.3%. Presumptive vaccination was the
preferred strategy (with an incremental cost-effectiveness ratio (ICER) of $7148 USD per infant protected)
in populations with poor vaccine compliance (where >80% of patients did not complete the full catch-up
vaccine series), or populations with low seroprevalence (<51%) of antibodies to diphtheria and tetanus.
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Table 2. Characteristics of Studies—Cost-Effectiveness of Vaccination Strategies.
Study Certainty of Economic Evidence(Quality) Design Population Intervention Cost-Effectiveness
Resource
Requirements
Cohen et al.
2006 [39]
Some allowance made for
uncertainty in the estimates of
c sts d consequences. The costs
are provided as base case, and 25%
upper and lower range
No probabilistic sensitivity
analyses performed.
Sensitivity analysis was
undertaken for costs of serotesting,
compliance rate and
seroprevalence.
Cost-effectiveness results were
sensitive to changes in
seroprevalence, cost of serotesting.
Decision-analytic
model; results
presented in 2004
US dollars
US 1. presumptive
vaccination with
IPV
2. serotesting for
poliovirus type 1,
2, and 3 antibodies
followed by
vaccination in
unprotected
patients
For IPV,
presumptive
vaccination is less
costly and more
effective, For Dtap,
ICER is $7148
USD per person
protected.
Difference in costs
between 2 interventions
ar small. For IPV,
difference in cost is very
minimal: Serotesting is
slightly more expensive
($5 USD) than
presumptive
vaccination. For Dtap,
serotesting is more
expensive than
presumptive vaccine
($57 USD)
4. Discussion
This systematic review identified few data on interventions to increase vaccina ons and
cost-effectiveness of vaccinations in migrant populations. Several interventions were identified as
potentially helpful to increase vaccination rates in migrant populations. The interventions focused
on social mobilization and outreach programs, planned vaccinations, and educational campaigns
similar to strategies used to improve vaccination rates in low to middle income countries in migrant
populations [40–44]. Overall, the interventions in this study described did not address all the vaccination
barriers in migrants such as: use of traditional health care [45], socioeconomic status [45], language [46],
distance o vaccination service [46,47], continued migration [47], fear of arrest [47], necessity of
work [47], lack of vaccination knowledge [46,48,49], cost [49], and lack of health care provider
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recommendation [50]. None of the interventions focused on health care providers. The interventions
were not targeted, having the same strategy for different migrant age groups and all of the interventions
were focused on groups of migrants, not at the level of the individual patient-healthcare interaction.
Additionally, none of the studies identified that they had engaged migrant populations in the planning
or execution of the intervention.
Vaccinations should not be provided in isolation, but the interaction should be viewed as an
opportunity to address many important diseases of public health significance [51]. Engaging refugees
and other migrant populations in preventive health services remains a challenge in light of the barriers
to healthcare [52,53]. A recent consensus statement on access to health services in the EU/EEA by
IOM’s EQUI HEALTH project [54] highlights the discrepancies in entitlements to statutory health
services for migrants; irregular migrants often have highly restrictive access.
The number of studies on the economic analysis for vaccinations in migrant populations is
even more limited. Only one study was applicable, suggesting that presumptive polio and DTaP
vaccination appear to be more cost effective and less expensive than pre-vaccination serotesting [39].
This modelling was done utilizing data from a very small and unique population of international
migrants, international adoptees. Although the economic analysis demonstrated cost effectiveness of
vaccination without serological testing, this group has significant resources and understanding of the
health systems and entitlements of the country of destination and engages with the health care system
on an individual basis. The cost effectiveness differed depending on the serological prevalence of the
VPDs and the compliance with vaccinations. Seroprevalence can vary depending on country of origin,
type of migrant and age of migrant making it difficult to extrapolate these data.
Two studies published after the economic analysis systematic review was performed examined
different costs associated with pre-departure vaccinations, one in the context of a response to an
outbreak [55] and the second evaluating the US Vaccination Program for US-bound Refugees (VPR) [56].
The first study showed that pre-departure vaccination of all US bound refugees would not only improve
health, reduce importations of VPD, but be cost saving when considering all the resources required for
response to outbreak activities. The second US study demonstrated that compared with post-arrival
vaccinations, the initiation of the pre-departure VPR where the refugees received one or two doses of
selected vaccines before departure and completed the series after arrival demonstrated a net savings
per person of $225.93 USD (29% decrease in vaccination costs). The cost savings were sensitive to
different variables but demonstrated cost savings across all the estimates. Although the European
context is not the same as the orderly US Refugee program, these data could be used to support the
vaccination in reception centres before the onward migration in the EU/EEA. Not only is it cost-saving,
but there is the potential to prevent unwanted and costly outbreaks of VPDs.
5. Strengths and Limitations
Our study is the first to our knowledge that is a systematic review on interventions that increase
vaccinations in migrant populations and cost effectiveness of vaccination strategies in migrant
populations. The studies that we found reflect the overall migration health literature of low quality with
many being cohort or pre-post studies and no negative studies or long term follow up studies. Other
limitations of our study are the lack of comparator data and the fact that the only reported outcome was
vaccine uptake. Given the complexities of immunisations in this vulnerable population, a short-term
increase in vaccine uptake does not directly translate into decreased VPD incidence or decrease in
outbreaks. Finally, there is difficulty in extrapolating this evidence across the very heterogeneous
group of migrants (undocumented migrant, refugee, asylum seeker, labour migrant, unaccompanied
children, etc.) with different pre-migration immunisation coverage, immunity, and age.
6. Implementation Considerations and Evidence Gaps
The lack of data on migrant specific variables (i.e., country of birth) related to VPDs [7,57–59] makes
estimation of the scope of vaccine delivery challenging. Small studies done in special circumstances have
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shown some sub-optimal vaccine coverage and immunity, but there is a limit to how these data can be
extrapolated to all migrants [16,18–20,22–24]. Robust surveillance data on vaccine preventable diseases
and vaccine coverage in migrant populations by age group, migration type, source country, and duration
of presence in the EU/EEA will be required to design effective immunisation programmes [57,58].
This will require a standardisation of migrant definitions and parameters. Further research on vaccination
uptake, immunisation coverage, and cost-effectiveness of different strategies in adults versus children
is required to inform potential different migrant guidelines [60]. The optimal method to document
immunisations and share immunisation data across jurisdictions in mobile populations to ensure that
the migrant receives the correct immunisations at the appropriate time is an understudied area [61].
Documentation could be done via a standardised health record or mobile immunisation record [62,63].
However, they need to be secure, private, and ensure that the information does not disadvantage or
be reason for persecution of the migrant. Engaging migrants in the development of interventions is
important to the development of effective interventions. Finally, evidence on the comparative effective
implementation strategies and cost-effectiveness of different vaccination strategies for migrants will be
required to prioritize the VPDs prevention efforts for the EU/EEA.
7. Conclusions
High quality studies assessing interventions to increase vaccinations and the cost effectiveness
of vaccinations in migrant populations are scarce. Data on migrant populations, vaccine preventable
diseases and vaccinations are required to estimate the scale of the problem and to understand the benefit
of interventions on a population scale. Large scale studies on interventions to improve vaccination
uptake among different typologies of migrants, and across their migration journey, are required to
inform the best and most equitable care of migrants. The economic analyses of these interventions are
crucial to inform their implementation.
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